Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 09, 2022

SELL
$0.32 - $0.74 $146,272 - $338,254
-457,100 Closed
0 $0
Q1 2022

May 12, 2022

SELL
$0.41 - $0.7 $20,205 - $34,496
-49,281 Reduced 9.73%
457,100 $228,000
Q4 2021

Feb 10, 2022

BUY
$0.53 - $1.03 $58,014 - $112,745
109,462 Added 27.58%
506,381 $287,000
Q3 2021

Nov 12, 2021

SELL
$1.0 - $1.18 $341,701 - $403,207
-341,701 Reduced 46.26%
396,919 $408,000
Q2 2021

Aug 11, 2021

BUY
$1.01 - $1.58 $530,938 - $830,577
525,682 Added 246.87%
738,620 $886,000
Q1 2021

May 11, 2021

BUY
$1.23 - $5.98 $261,913 - $1.27 Million
212,938 New
212,938 $277,000
Q3 2020

Nov 09, 2020

SELL
$1.71 - $2.68 $64,915 - $101,738
-37,962 Closed
0 $0
Q2 2020

Aug 12, 2020

SELL
$1.23 - $2.12 $44,078 - $75,972
-35,836 Reduced 48.56%
37,962 $68,000
Q1 2020

May 11, 2020

SELL
$1.06 - $2.15 $58,436 - $118,527
-55,129 Reduced 42.76%
73,798 $98,000
Q4 2019

Feb 06, 2020

SELL
$1.45 - $2.79 $45,028 - $86,640
-31,054 Reduced 19.41%
128,927 $235,000
Q3 2019

Nov 07, 2019

SELL
$2.12 - $3.31 $10,733 - $16,758
-5,063 Reduced 3.07%
159,981 $462,000
Q2 2019

Aug 08, 2019

BUY
$2.37 - $3.97 $286,440 - $479,818
120,861 Added 273.55%
165,044 $440,000
Q1 2019

May 09, 2019

BUY
$2.33 - $3.79 $102,946 - $167,453
44,183 New
44,183 $113,000
Q4 2018

Feb 07, 2019

SELL
$2.77 - $9.38 $10,113 - $34,246
-3,651 Closed
0 $0
Q3 2018

Oct 30, 2018

BUY
$5.53 - $11.36 $20,190 - $41,475
3,651 New
3,651 $33,000

Others Institutions Holding IDRA

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0

About IDERA PHARMACEUTICALS, INC.


  • Ticker IDRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,296,900
  • Market Cap $188M
  • Description
  • Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating s...
More about IDRA
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.